Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells – with a cell-killing drug called monomethyl auristatin E.

Based on topline data, ZLAB said Tivdak, an antibody-drug conjugate, cut mortality risk by 45% in Chinese patients who had previously received standard systemic therapies. The Shanghai-based ...

(RTTNews) - Zai Lab Limited (ZLAB) announced that China's National Medical Products Administration or NMPA has accepted the Biologics License Application or BLA for TIVDAK (tisotumab vedotin-tftv ...

With a portfolio of marketed products, including EPKINLY, TEPKINLY, and Tivdak, and a robust pipeline featuring Epcoritamab and tisotumab vedotin, it’s advancing groundbreaking treatments in ...

Share Buyback: $500 million in 2024. EPKINLY Sales: $281 million in 2024. Tivdak Sales: $131 million in 2024. Recurring Revenue Growth: 35% increase in 2024. DARZALEX Net Sales: Nearly $11.7 ...

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688 ...